Featured Courses

Ring Sideroblast Quantification in Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Symposium on pathology of MDS-RS includes a cross-disciplinary interview enhanced by infographics and pathologist pocket guide. Exp 4/28/2023

Optimal Therapy for Vulnerable Follicular Lymphoma Patients | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists, AAPA Category I CME Credit

0.50 CME CE: This final installment in a 3-part series assesses the needs of older patients with FL when creating treatment plans. Exp. 3/9/2023

Management of Follicular Lymphoma | myCME

ANCC Contact Hour(s)

1.50 CE: Focuses on oncology nurse role in FL and discusses advances treatment, including updates to guidelines and two novel agents. Exp 4/29/23

Beta Thalassemia Advances : Reducing Transfusion Burden | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: This interactive e-journal article covers pathophysiology, diagnostic criteria, clinical trial data, and transition preparedness strategies. Exp 3/11/2023

Optimizing Outcomes in Low-Risk MDS | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: In-depth discussion for healthcare practitioners who manage patients with low-risk MDS so they can to better recognize the types of MDS. Exp 4/29/23

Targeted Therapy for NSCLC: New Frontiers | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: Dr. Marianne Davies discusses current molecular testing guidelines; molecular profile-based, targeted-treatment strategies; and more. Exp 4/29/23

Antibody-drug Conjugates and Ocular Toxicity | myCME

AMA PRA Category 1 Credit(s)^TM

1.25 CME: Expert faculty provides guidelines on monitoring and managing corneal toxicities due to antibody-drug conjugates. Exp 1/4/23

Tackling EGFR Exon 20 Insertion Mutations in NSCLC | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Harvard’s Zofia Piotrowska, MD, discusses exciting new and emerging targeted therapies for patients with ex20ins mutations. Exp 2/23/23

Endometrial Cancer Treatment and Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME: Experts debate and discuss molecular testing, clinical data, treatment selection, and patient management in endometrial cancer. Exp 2/24/23

Novel Targets for Higher-risk Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Examine clinical data supporting the importance of differential diagnosis, risk stratification, and emerging therapies. Exp 2/24/23

A Multidisciplinary Approach to Cervical Cancer Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s)

1.50 CME CE: New therapies, new sequencing and management strategies, and a critical need for expert guidance are shifting CC treatment. Exp 4/23/23

BTK Inhibition in CLL: Interactive Self-Assessment | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s), IPCE Credit(s)

0.75 CME CE: Bruton tyrosine kinase inhibitors are crucial in treating CLL. This interactive course reviews latest evidence and practice guidance. Exp 6/28/23